MCID: TRN018
MIFTS: 62

Transitional Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Transitional Cell Carcinoma

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 12 77 54 15 17
Carcinoma, Transitional Cell 45 74
Transitional Cell Neoplasm 12 74
Transitional Cell Carcinoma of Bladder 74
Carcinoma Transitional Cell 56
Urothelial Cell Carcinoma 12
Transitional Cell Tumor 12
Transitional Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2671
MeSH 45 D002295
NCIt 51 C2930 C6783
SNOMED-CT 69 27090000

Summaries for Transitional Cell Carcinoma

Disease Ontology : 12 A carcinoma that derives from transitional epithelial cells.

MalaCards based summary : Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to renal pelvis transitional cell carcinoma and bladder papillary transitional cell neoplasm. An important gene associated with Transitional Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Vinblastine and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include kidney, lymph node and ovary, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Transitional cell carcinoma, also urothelial carcinoma, is a type of cancer that typically occurs in the... more...

Related Diseases for Transitional Cell Carcinoma

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 425, show less)
# Related Disease Score Top Affiliating Genes
1 renal pelvis transitional cell carcinoma 34.2 KRT7 UPK3A
2 bladder papillary transitional cell neoplasm 34.0 FGFR3 KRT20 TP53
3 papillary transitional carcinoma 33.9 KRT20 KRT7
4 small cell carcinoma of the bladder 33.1 KRT20 KRT7
5 bladder urothelial carcinoma 32.7 CDH1 ERBB2 FGFR3 HRAS KRT20 KRT7
6 urinary tract papillary transitional cell benign neoplasm 32.4 FGFR3 KRT20 TP53
7 glandular cystitis 32.2 KRT20 KRT7 UPK3A
8 prostate cancer 31.5 CDH1 EGFR ERBB2 ERBB3 HRAS KRT18
9 in situ carcinoma 30.9 CDH1 CDKN2A EGFR ERBB2 TP53
10 bladder cancer 30.9 BRINP1 CDH1 CDKN2A EGFR ERBB2 FGFR3
11 inverted papilloma 30.6 CDKN2A KRT20 KRT7 TP53
12 papilloma 30.5 CDKN2A FGFR3 KRT20 KRT7 PTEN TP53
13 mammary paget's disease 30.4 EGFR ERBB2 KRT20 KRT7
14 myeloma, multiple 30.4 CDKN2A FGFR3 HRAS TP53
15 bladder squamous cell carcinoma 30.4 CDKN2A TP53 UPK2
16 renal cell carcinoma, nonpapillary 30.4 CDH1 EGFR IFNA2 KRT20 KRT7
17 merkel cell carcinoma 30.3 KRT20 KRT7 TP53
18 cervix carcinoma 30.3 CDKN2A FGFR3 TP53
19 cystitis 30.3 KRT20 PTGS2 UPK1A UPK3A
20 ovarian cancer 1 30.3 CDH1 ERBB2 KRT7 TP53
21 appendix adenocarcinoma 30.2 KRT20 KRT7
22 clear cell renal cell carcinoma 30.2 CDH1 KRT7 PTEN TP53
23 adenocarcinoma 30.2 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
24 paget disease, extramammary 30.1 ERBB2 KRT20 KRT7
25 non-invasive bladder papillary urothelial neoplasm 30.1 FGFR3 TP53 UPK3A
26 horseshoe kidney 30.1 EGFR KRT20 KRT7
27 suppression of tumorigenicity 12 30.0 CDH1 HRAS PTEN TP53 UPK3A
28 vesicoureteral reflux 1 30.0 UPK1A UPK1B UPK3A
29 cystadenocarcinoma 30.0 ERBB2 HRAS KRT7 TP53
30 squamous cell carcinoma 30.0 CDH1 CDKN2A EGFR ERBB2 FGFR3 HRAS
31 linitis plastica 29.9 CDH1 KRT20 KRT7
32 papillary adenocarcinoma 29.9 CDH1 ERBB2 KRT7 TP53
33 small cell carcinoma 29.9 CDKN2A EGFR KRT20 KRT7 PTEN TP53
34 carcinosarcoma 29.9 ERBB2 HRAS KRT7 PTEN TP53
35 ovarian brenner tumor 29.8 KRT18 KRT20 KRT7 UPK3A
36 mucinous adenocarcinoma 29.8 CDKN2A EGFR KRT20 KRT7
37 renal cell carcinoma, papillary, 1 29.7 ERBB2 FGFR3 HRAS KRT7 PTEN TP53
38 endometrial cancer 29.6 CDH1 CDKN2A EGFR ERBB2 HRAS KRT7
39 ovarian cancer 29.6 CDH1 EGFR ERBB2 ERBB3 KRT7 PTEN
40 cervical adenocarcinoma 29.5 CDKN2A ERBB2 KRT20 KRT7 PTGS2 TP53
41 adenoid cystic carcinoma 29.4 CDH1 ERBB2 HRAS KRT20 KRT7 PTEN
42 bladder disease 29.1 CDH1 CDKN2A ERBB2 FGFR3 KRT20 TP53
43 hepatocellular carcinoma 28.7 CDH1 CDKN2A EGFR HRAS KRT7 PTEN
44 cholangiocarcinoma 28.6 CDH1 CDKN2A EGFR ERBB2 KRT18 KRT20
45 lung cancer 28.5 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
46 colorectal cancer 28.4 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
47 sarcomatoid transitional cell carcinoma 12.6
48 ureter transitional cell carcinoma 12.5
49 ovary transitional cell carcinoma 12.5
50 infiltrating renal pelvis transitional cell carcinoma 12.4
51 prostate transitional cell carcinoma 12.4
52 urethra transitional cell carcinoma 12.4
53 invasive bladder transitional cell carcinoma 12.4
54 fallopian tube transitional cell carcinoma 12.4
55 non-papillary transitional cell carcinoma of the bladder 12.3
56 bartholin's gland transitional cell carcinoma 12.3
57 endometrial transitional cell carcinoma 12.3
58 transitional cell carcinoma of the corpus uteri 12.3
59 kidney pelvis sarcomatoid transitional cell carcinoma 12.3
60 urinary tract non-invasive transitional cell neoplasm 12.2
61 infiltrating ureter transitional cell carcinoma 12.2
62 prostate cancer, hereditary, 1 11.2
63 prostate cancer, hereditary, 12 11.2
64 prostate cancer, hereditary, 13 11.2
65 prostate cancer, hereditary, 11 11.2
66 prostate cancer, hereditary, 2 11.2
67 fallopian tube carcinoma 11.2
68 urachal cancer 11.2
69 urethral cancer 11.2
70 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
71 breast papillomatosis 10.6 CDKN2A ERBB2
72 fallopian tube endometrioid adenocarcinoma 10.6 CDKN2A ERBB2
73 cerebral convexity meningioma 10.6 CDH1 TP53
74 bartholin's gland benign neoplasm 10.6 CDKN2A ERBB3
75 breast cystic hypersecretory carcinoma 10.6 CDH1 ERBB2
76 paronychia 10.6 EGFR HRAS
77 brain ependymoma 10.5 EGFR TP53
78 progesterone-receptor negative breast cancer 10.5 EGFR ERBB2
79 breast intraductal proliferative lesion 10.5 EGFR ERBB2
80 colloid adenoma 10.5 KRT20 TP53
81 breast scirrhous carcinoma 10.5 EGFR ERBB2
82 protoplasmic astrocytoma 10.5 PTGS2 TP53
83 malignant peritoneal mesothelioma 10.5 CDKN2A EGFR
84 serous cystadenocarcinoma 10.5 ERBB2 HRAS TP53
85 malignant spiradenoma 10.5 KRT7 TP53
86 vulvar intraepithelial neoplasia 10.5 KRT7 TP53
87 ovarian serous cystadenocarcinoma 10.5 ERBB2 HRAS TP53
88 skin squamous cell carcinoma 10.5 CDKN2A HRAS TP53
89 inverted transitional papilloma 10.5 CDKN2A KRT7
90 sporadic breast cancer 10.5 ERBB2 PTEN TP53
91 conjunctival intraepithelial neoplasm 10.5 CDKN2A IFNA2
92 renal pelvis adenocarcinoma 10.5 CDH1 KRT7
93 cervical squamous cell carcinoma 10.5 CDH1 CDKN2A TP53
94 tongue squamous cell carcinoma 10.5 CDH1 CDKN2A TP53
95 cervix disease 10.5 CDH1 CDKN2A TP53
96 male reproductive organ cancer 10.5 CDH1 PTEN TP53
97 benign breast adenomyoepithelioma 10.5 EGFR KRT7
98 tongue cancer 10.5 CDH1 CDKN2A TP53
99 estrogen-receptor positive breast cancer 10.5 EGFR ERBB2 TP53
100 nasopharyngeal disease 10.5 CDH1 CDKN2A TP53
101 exanthem 10.5 EGFR ERBB2 HRAS
102 oncocytic breast carcinoma 10.5 EGFR KRT7
103 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
104 transverse colon cancer 10.5 KRT20 KRT7
105 differentiated thyroid carcinoma 10.5 EGFR HRAS TP53
106 tarsal-carpal coalition syndrome 10.5
107 cystic basal cell carcinoma 10.4 KRT20 KRT7
108 colorectal adenoma 10.4 HRAS PTGS2 TP53
109 malignant syringoma 10.4 KRT20 KRT7
110 breast carcinoma in situ 10.4 EGFR ERBB2 TP53
111 eyelid carcinoma 10.4 KRT20 KRT7
112 lung acinar adenocarcinoma 10.4 KRT20 KRT7
113 primary peritoneal carcinoma 10.4 EGFR ERBB2 TP53
114 intestinal benign neoplasm 10.4 HRAS PTGS2 TP53
115 malignant peripheral nerve sheath tumor 10.4 CDKN2A EGFR TP53
116 male reproductive system disease 10.4 CDH1 PTEN TP53
117 krukenberg carcinoma 10.4 KRT20 KRT7
118 spitz nevus 10.4 CDKN2A HRAS TP53
119 ovarian clear cell carcinoma 10.4 KRT7 PTEN TP53
120 tubular adenocarcinoma 10.4 CDH1 ERBB2 KRT20
121 proliferating trichilemmal cyst 10.4 KRT18 KRT7
122 meningeal melanomatosis 10.4 CDKN2A HRAS TP53
123 bartholin's gland disease 10.4 CDKN2A ERBB3 TP53
124 breast squamous cell carcinoma 10.4 EGFR ERBB2 TP53
125 bile duct cancer 10.4 EGFR KRT7 TP53
126 pseudomyxoma peritonei 10.4 KRT20 KRT7 TP53
127 small intestine cancer 10.4 HRAS KRT20 KRT7
128 cecum adenocarcinoma 10.4 HRAS KRT20 KRT7
129 mucoepidermoid carcinoma 10.4 EGFR ERBB2 KRT7
130 gastrointestinal stromal tumor 10.3 CDKN2A EGFR PTEN TP53
131 adenosquamous carcinoma 10.3 EGFR KRT7 TP53
132 cystitis cystica 10.3 KRT20 KRT7 UPK2
133 signet ring cell adenocarcinoma 10.3 CDH1 KRT20 KRT7
134 recurrent respiratory papillomatosis 10.3 EGFR PTGS2 TP53
135 testicular germ cell tumor 10.3 FGFR3 HRAS PTEN TP53
136 prostate squamous cell carcinoma 10.3 HRAS KRT7 TP53
137 adenosquamous lung carcinoma 10.3 EGFR ERBB2 FGFR3 HRAS
138 esophagus adenocarcinoma 10.3 ERBB2 PTGS2 TP53
139 large cell neuroendocrine carcinoma 10.3 EGFR KRT20 KRT7
140 acneiform dermatitis 10.3 EGFR ERBB2 HRAS
141 inflammatory breast carcinoma 10.3 CDH1 EGFR ERBB2
142 female reproductive endometrioid cancer 10.3 KRT7 PTEN TP53
143 pharynx cancer 10.3 CDH1 CDKN2A EGFR TP53
144 giant cell glioblastoma 10.3 EGFR FGFR3 PTEN TP53
145 gliomatosis cerebri 10.3 EGFR PTEN TP53
146 mucinous lung adenocarcinoma 10.3 EGFR ERBB2 ERBB3 HRAS
147 nasal cavity adenocarcinoma 10.3 CDKN2A HRAS KRT7 TP53
148 barrett's adenocarcinoma 10.3 CDKN2A ERBB2 PTGS2 TP53
149 luminal breast carcinoma 10.3 EGFR ERBB2 ERBB3
150 mixed cell type cancer 10.3 ERBB2 HRAS KRT7 TP53
151 supratentorial cancer 10.3 CDKN2A EGFR PTEN TP53
152 cerebrum cancer 10.3 CDKN2A EGFR PTEN TP53
153 ovary adenocarcinoma 10.3 ERBB2 HRAS KRT7 TP53
154 laryngeal disease 10.3 CDH1 CDKN2A EGFR TP53
155 appendix disease 10.3 HRAS KRT20 KRT7
156 sarcomatoid renal cell carcinoma 10.3 CDH1 IFNA2 TP53
157 grade iii astrocytoma 10.3 CDKN2A EGFR PTEN TP53
158 central nervous system cancer 10.3 CDKN2A EGFR PTEN TP53
159 nervous system cancer 10.3 CDKN2A EGFR PTEN TP53
160 papillary serous adenocarcinoma 10.3 KRT20 KRT7 TP53
161 bladder carcinoma in situ 10.3 CDKN2A KRT7 TP53 UPK2
162 bile duct adenoma 10.3 CDKN2A KRT20 KRT7
163 bladder adenocarcinoma 10.3 HRAS KRT20 KRT7
164 gliosarcoma 10.3 EGFR FGFR3 PTEN TP53
165 large intestine adenocarcinoma 10.3 CDH1 KRT20 KRT7
166 cell type benign neoplasm 10.3 CDKN2A HRAS KRT7 TP53
167 adenoid squamous cell carcinoma 10.2 CDH1 KRT20 KRT7
168 bile duct adenocarcinoma 10.2 CDH1 HRAS KRT7 TP53
169 pleomorphic carcinoma 10.2 EGFR KRT7 TP53
170 laryngeal squamous cell carcinoma 10.2 CDH1 CDKN2A EGFR TP53
171 li-fraumeni syndrome 10.2 CDKN2A EGFR PTEN TP53
172 breast ductal carcinoma 10.2 CDH1 EGFR ERBB2 TP53
173 biliary papillomatosis 10.2 HRAS KRT20 KRT7 TP53
174 nasopharyngeal carcinoma 10.2 CDH1 CDKN2A EGFR HRAS TP53
175 epithelial-myoepithelial carcinoma 10.2 HRAS KRT7 TP53
176 penile disease 10.2 CDKN2A IFNA2 TP53
177 respiratory system disease 10.2 CDH1 EGFR HRAS TP53
178 hidradenocarcinoma 10.2 EGFR ERBB2 KRT7 TP53
179 uterine anomalies 10.2 CDH1 CDKN2A ERBB2 PTEN TP53
180 medulloblastoma 10.2 EGFR ERBB2 ERBB3 PTEN TP53
181 mucinous bronchioloalveolar adenocarcinoma 10.2 CDKN2A KRT20 KRT7
182 ampulla of vater cancer 10.2 HRAS KRT20 KRT7 TP53
183 thyroid cancer 10.2 CDH1 EGFR HRAS PTEN TP53
184 meningioma, familial 10.2 CDH1 CDKN2A PTEN TP53
185 basaloid squamous cell carcinoma 10.2 CDKN2A EGFR KRT7 TP53
186 lung benign neoplasm 10.2 EGFR HRAS KRT7 TP53
187 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A KRT20 KRT7 TP53
188 actinic keratosis 10.2 CDKN2A KRT20 PTGS2 TP53
189 endocervical adenocarcinoma 10.2 CDKN2A KRT20 KRT7 TP53
190 lipid-rich carcinoma 10.2 CDH1 EGFR ERBB2
191 gastrointestinal system benign neoplasm 10.2 HRAS KRT7 PTGS2 TP53
192 eccrine sweat gland neoplasm 10.2 KRT20 KRT7 TP53
193 microglandular adenosis 10.2 EGFR ERBB2 KRT18 TP53
194 vulvar disease 10.2 CDKN2A KRT7 TP53 UPK3A
195 pancreatic ductal carcinoma 10.2 CDKN2A KRT20 KRT7 TP53
196 oligodendroglioma 10.2 CDKN2A EGFR PTEN TP53
197 pre-malignant neoplasm 10.2 CDH1 CDKN2A EGFR ERBB2 TP53
198 necrotizing sialometaplasia 10.2 CDKN2A KRT7 TP53
199 penile cancer 10.2 CDKN2A EGFR IFNA2 TP53
200 tongue disease 10.2 CDH1 CDKN2A TP53
201 cholecystitis 10.2 CDH1 CDKN2A KRT18 TP53
202 dermatomyositis 10.2
203 squamous cell papilloma 10.2
204 gastric diffuse adenocarcinoma 10.2 CDH1 KRT20 KRT7 UPK2
205 oral cavity cancer 10.2 CDH1 EGFR ERBB2 PTEN TP53
206 appendix cancer 10.2 KRT20 KRT7 TP53
207 chronic cystitis 10.2 KRT20 KRT7 UPK3A
208 breast adenocarcinoma 10.2 EGFR ERBB2 PTEN TP53
209 malignant ovarian surface epithelial-stromal neoplasm 10.2 CDH1 ERBB2 HRAS KRT7 TP53
210 ovary epithelial cancer 10.2 CDH1 ERBB2 HRAS KRT7 TP53
211 renal pelvis carcinoma 10.2 KRT20 KRT7 UPK3A
212 infiltrative basal cell carcinoma 10.2 CDH1 KRT20 KRT7
213 tonsil cancer 10.2 CDH1 CDKN2A ERBB2 KRT7 TP53
214 esophageal disease 10.2 CDKN2A EGFR ERBB2 PTGS2 TP53
215 cervical adenosquamous carcinoma 10.1 CDKN2A EGFR KRT7 PTGS2
216 glioblastoma multiforme 10.1 CDKN2A EGFR ERBB2 PTEN TP53
217 papillary carcinoma 10.1 CDH1 ERBB2 KRT20 KRT7
218 colonic disease 10.1 CDH1 EGFR HRAS PTGS2 TP53
219 cystic teratoma 10.1 KRT20 KRT7 TP53
220 hydronephrosis 10.1
221 ductal carcinoma in situ 10.1 CDH1 EGFR ERBB2 PTGS2 TP53
222 intestinal disease 10.1 CDH1 EGFR HRAS PTGS2 TP53
223 stomach disease 10.1 CDH1 EGFR ERBB2 PTGS2 TP53
224 pancreatic cancer 10.1 CDH1 CDKN2A EGFR ERBB2 HRAS TP53
225 melanoma, cutaneous malignant 1 10.1 CDKN2A HRAS IFNA2 PTEN TP53
226 bronchiolo-alveolar adenocarcinoma 10.1 CDH1 EGFR KRT20 KRT7
227 oral cancer 10.1 CDH1 CDKN2A EGFR PTGS2 TP53
228 oropharynx cancer 10.1 CDH1 CDKN2A EGFR KRT7 TP53
229 pancreatic mucinous cystadenoma 10.1 HRAS KRT20 KRT7
230 lymphoma 10.1
231 glioma 10.1 CDKN2A EGFR ERBB2 PTEN TP53
232 lung squamous cell carcinoma 10.1 CDH1 EGFR FGFR3 HRAS PTEN TP53
233 female reproductive system disease 10.1 CDH1 CDKN2A EGFR ERBB2 PTEN TP53
234 chordoma 10.1 CDH1 CDKN2A EGFR KRT7 PTEN
235 lymphoepithelioma-like carcinoma 10.1 CDH1 KRT18 KRT20 KRT7
236 vulva cancer 10.1 CDKN2A EGFR KRT7 TP53 UPK3A
237 choriocarcinoma 10.1
238 amyloidosis 10.1
239 intrahepatic cholangiocarcinoma 10.1 CDH1 EGFR KRT20 KRT7 TP53
240 vulval paget's disease 10.1 CDKN2A ERBB2 KRT20 KRT7 UPK3A
241 vulva adenocarcinoma 10.0 CDKN2A ERBB2 KRT20 KRT7 UPK3A
242 gallbladder cancer 10.0 CDH1 CDKN2A EGFR ERBB2 PTGS2 TP53
243 endometrial adenocarcinoma 10.0 CDKN2A EGFR ERBB2 KRT7 PTEN TP53
244 osteomyelitis 10.0
245 sweat gland cancer 10.0 ERBB2 KRT18 KRT20 KRT7 TP53
246 ovarian cystic teratoma 10.0 IFNA2 KRT20 KRT7
247 intussusception 10.0
248 pyelonephritis 10.0
249 leiomyosarcoma 10.0
250 adenoma 10.0
251 meningitis 10.0
252 urachal cyst 10.0
253 respiratory system cancer 10.0 CDH1 CDKN2A EGFR ERBB2 HRAS PTEN
254 endocrine gland cancer 10.0 CDH1 CDKN2A EGFR ERBB2 HRAS PTEN
255 glioblastoma 10.0 CDKN2A EGFR ERBB2 ERBB3 HRAS PTEN
256 barrett esophagus 10.0 CDKN2A ERBB2 KRT20 KRT7 PTGS2 TP53
257 aortic aneurysm, familial abdominal, 1 10.0
258 retinoblastoma 10.0
259 ureterocele 10.0
260 thrombosis 10.0
261 xanthogranulomatous pyelonephritis 10.0
262 nephrotic syndrome 10.0
263 melanoma 10.0
264 giant cell tumor 10.0
265 aortic aneurysm 10.0
266 lynch syndrome 10.0
267 spindle cell carcinoma 10.0
268 ureteral obstruction 10.0
269 kidney disease 10.0
270 priapism 10.0
271 urethral diverticulum 10.0
272 lymphomatous meningitis 10.0
273 adenocarcinoma in situ 9.9 CDKN2A KRT20 KRT7
274 gastrointestinal system disease 9.9 CDH1 CDKN2A EGFR ERBB2 HRAS PTGS2
275 pancreas adenocarcinoma 9.9 CDH1 CDKN2A EGFR ERBB2 HRAS PTGS2
276 reproductive system disease 9.9 CDH1 CDKN2A EGFR ERBB2 PTEN PTGS2
277 adamantinoma of long bones 9.9 CDH1 CDKN2A EGFR ERBB2 PTEN PTGS2
278 granulosa cell tumor of the ovary 9.9 ERBB2 KRT7 TP53
279 cervical cancer 9.9 CDH1 CDKN2A ERBB2 FGFR3 HRAS PTEN
280 mutagen sensitivity 9.9
281 pyuria 9.9
282 rectum adenocarcinoma 9.9
283 spindle cell sarcoma 9.9
284 acanthosis nigricans 9.9
285 bladder diverticulum 9.9
286 muir-torre syndrome 9.9
287 nevus, epidermal 9.9
288 chondrosarcoma 9.9
289 lambert-eaton myasthenic syndrome 9.9
290 leiomyoma 9.9
291 bladder leiomyoma 9.9
292 interstitial cystitis 9.9
293 malignant fibroxanthoma 9.9
294 turner syndrome 9.9
295 malignant ovarian brenner tumor 9.9
296 histiocytoma 9.9
297 fibrous histiocytoma 9.9
298 collecting duct carcinoma 9.9
299 clear cell adenocarcinoma 9.9
300 nephrogenic adenoma 9.9
301 autosomal dominant polycystic kidney disease 9.9
302 polycystic kidney disease 9.9
303 brenner tumor of ovary 9.9
304 degos 'en cocarde' erythrokeratoderma 9.9
305 undifferentiated pleomorphic sarcoma 9.9
306 hypoxia 9.9
307 hinman syndrome 9.9
308 pituitary adenoma 9.8
309 uterine carcinosarcoma 9.8 CDH1 EGFR ERBB2 ERBB3 HRAS PTEN
310 esophageal cancer 9.8 CDH1 CDKN2A EGFR ERBB2 HRAS PTEN
311 colorectal adenocarcinoma 9.8 CDH1 EGFR HRAS KRT20 KRT7 PTGS2
312 small cell cancer of the lung 9.8 CDKN2A EGFR KRT18 KRT20 KRT7 PTEN
313 gastric cancer 9.7 CDH1 CDKN2A EGFR ERBB2 KRT20 PTEN
314 breast cancer 9.7
315 congenital anomalies of kidney and urinary tract 2 9.7
316 endosteal hyperostosis, autosomal dominant 9.7
317 hypochondroplasia 9.7
318 inclusion body myositis 9.7
319 systemic lupus erythematosus 9.7
320 myositis 9.7
321 costello syndrome 9.7
322 enterocolitis 9.7
323 factor x deficiency 9.7
324 hemangiopericytoma, malignant 9.7
325 indifference to pain, congenital, autosomal recessive 9.7
326 osteogenic sarcoma 9.7
327 renal dysplasia, cystic 9.7
328 acute insulin response 9.7
329 prostate cancer, hereditary, 8 9.7
330 light fixation seizure syndrome 9.7
331 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
332 headache associated with sexual activity 9.7
333 prostate cancer, hereditary, 6 9.7
334 ewing sarcoma 9.7
335 aspergillosis 9.7
336 blood group, junior system 9.7
337 polyglucosan body myopathy 1 with or without immunodeficiency 9.7
338 acute liver failure 9.7
339 chronic kidney failure 9.7
340 crohn's disease 9.7
341 diabetes mellitus 9.7
342 end stage renal failure 9.7
343 hemangioma 9.7
344 liver disease 9.7
345 male infertility 9.7
346 neutropenia 9.7
347 polycystic ovary syndrome 9.7
348 spinal cord injury 9.7
349 angiosarcoma 9.7
350 cd40 ligand deficiency 9.7
351 atypical autism 9.7
352 colitis 9.7
353 obstructive nephropathy 9.7
354 dirofilariasis 9.7
355 sarcoma 9.7
356 hemopericardium 9.7
357 infant gynecomastia 9.7
358 pericardial effusion 9.7
359 neurogenic bladder 9.7
360 gynecomastia 9.7
361 acute cystitis 9.7
362 ehlers-danlos syndrome 9.7
363 tuberous sclerosis 9.7
364 urinary schistosomiasis 9.7
365 schistosomiasis 9.7
366 cholera 9.7
367 ichthyosis 9.7
368 neuroendocrine carcinoma 9.7
369 giant cell reparative granuloma 9.7
370 colon adenocarcinoma 9.7
371 renal adenoma 9.7
372 hemangioma of liver 9.7
373 endometriosis 9.7
374 cystic kidney disease 9.7
375 testicular cancer 9.7
376 papillary cystadenocarcinoma 9.7
377 duodenal obstruction 9.7
378 extramedullary plasmacytoma 9.7
379 plasmacytoma 9.7
380 hidradenoma 9.7
381 syphilis 9.7
382 seminoma 9.7
383 prostate adenoid cystic carcinoma 9.7
384 urinary tract obstruction 9.7
385 infertility 9.7
386 myxoid leiomyosarcoma 9.7
387 eccrine acrospiroma 9.7
388 cloacogenic carcinoma 9.7
389 appendicitis 9.7
390 bullous pemphigoid 9.7
391 acute cor pulmonale 9.7
392 herpes simplex 9.7
393 vasculitis 9.7
394 diabetes insipidus 9.7
395 fasciitis 9.7
396 renal tuberculosis 9.7
397 miliary tuberculosis 9.7
398 acrospiroma 9.7
399 cerebellar degeneration 9.7
400 chromophil renal cell carcinoma 9.7
401 enterovesical fistula 9.7
402 ichthyosis, acquired 9.7
403 lymphangiectasis 9.7
404 lymphatic malformations 9.7
405 lymphomatoid papulosis 9.7
406 malakoplakia 9.7
407 medullary sponge kidney 9.7
408 paraneoplastic cerebellar degeneration 9.7
409 penile cancer, adult 9.7
410 polymyositis 9.7
411 prurigo nodularis 9.7
412 testicular seminoma 9.7
413 xp22.3 microdeletion syndrome 9.7
414 encephalopathy 9.7
415 multicystic dysplastic kidney 9.7
416 primary localized amyloidosis 9.7
417 eosinophilic colitis 9.7
418 pituitary adenoma, prolactin-secreting 9.7
419 acromegaly 9.7
420 ureter inverted papilloma 9.7
421 gastrointestinal system cancer 9.7 CDH1 CDKN2A EGFR ERBB2 HRAS KRT7
422 squamous cell carcinoma, head and neck 9.6 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
423 gastric adenocarcinoma 9.5 CDH1 CDKN2A EGFR ERBB2 HRAS KRT20
424 lung cancer susceptibility 3 9.4 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
425 large intestine cancer 9.4 CDH1 CDKN2A EGFR ERBB2 ERBB3 HRAS

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma

Symptoms & Phenotypes for Transitional Cell Carcinoma

GenomeRNAi Phenotypes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

27 (showing 9, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.96 EGFR HRAS
2 Decreased viability GR00221-A-1 9.96 CDH1 CDKN2A EGFR FGFR3 HRAS
3 Decreased viability GR00221-A-2 9.96 FGFR3 HRAS
4 Decreased viability GR00221-A-3 9.96 CDKN2A FGFR3 HRAS
5 Decreased viability GR00221-A-4 9.96 CDKN2A EGFR
6 Decreased viability GR00301-A 9.96 CDH1
7 Decreased viability GR00402-S-2 9.96 CDH1 CDKN2A EGFR FGFR3 HRAS
8 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 EGFR ERBB2 FGFR3 HRAS PTEN
9 Reduced mammosphere formation GR00396-S 9.28 BRINP1 CDH1 EGFR ERBB3 HRAS KRT18

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

47 (showing 15, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
2 growth/size/body region MP:0005378 10.34 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
3 cellular MP:0005384 10.29 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
4 mortality/aging MP:0010768 10.28 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
5 digestive/alimentary MP:0005381 10.24 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
6 embryo MP:0005380 10.22 CDH1 CDKN2A EGFR ERBB2 ERBB3 KRT18
7 endocrine/exocrine gland MP:0005379 10.16 CDH1 CDKN2A EGFR ERBB2 ERBB3 HRAS
8 integument MP:0010771 10.16 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
9 neoplasm MP:0002006 10.1 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
10 normal MP:0002873 10.02 CDH1 EGFR ERBB2 ERBB3 FGFR3 HRAS
11 no phenotypic analysis MP:0003012 9.97 BRINP1 CDH1 CDKN2A EGFR FGFR3 HRAS
12 renal/urinary system MP:0005367 9.81 EGFR FGFR3 HRAS KRT7 PTEN PTGS2
13 pigmentation MP:0001186 9.65 CDKN2A EGFR ERBB3 PTEN TP53
14 respiratory system MP:0005388 9.61 CDKN2A EGFR ERBB2 ERBB3 FGFR3 HRAS
15 skeleton MP:0005390 9.28 BRINP1 CDKN2A EGFR ERBB2 FGFR3 HRAS

Drugs & Therapeutics for Transitional Cell Carcinoma

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 340, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 2, Phase 3,Phase 3,Phase 1 865-21-4 241903 13342
2
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
4
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Panitumumab Approved, Investigational Phase 3,Phase 2 339177-26-3 50070211
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
8
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 5280965 14956
9
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
10
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
11
Valrubicin Approved Phase 3,Phase 2,Phase 1 56124-62-0 41744
12
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
13
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
14
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
15
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
16
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
17
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1380723-44-3
18
Aminolevulinic acid Approved Phase 3 106-60-5 137
19
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
20
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
21
Pembrolizumab Approved Phase 3,Phase 1,Phase 2,Early Phase 1 1374853-91-4
22
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
24
Hydroxocobalamin Approved Phase 3,Phase 2,Not Applicable 13422-51-0 15589840 11953898
25
Methylcobalamin Approved, Experimental, Investigational Phase 3,Phase 2 13422-55-4
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
27
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
28
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 6251 453
29
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
30
Sargramostim Approved, Investigational Phase 2, Phase 3,Phase 1 123774-72-1, 83869-56-1
31
Lenvatinib Approved, Investigational Phase 3,Phase 1,Phase 2 417716-92-8
32
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
33
Durvalumab Approved, Investigational Phase 3,Phase 1,Phase 2 1428935-60-7
34
Olaparib Approved Phase 2, Phase 3,Phase 3,Phase 1 763113-22-0 23725625
35
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
36
Ethanol Approved Phase 3 64-17-5 702
37
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
38
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
41
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
42
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
43
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2,Not Applicable 68-19-9 44176380
44
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2 56-86-0 33032
45
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
46
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
47 Tocotrienol Investigational Phase 3 6829-55-6
48
BCG vaccine Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
49
Fenretinide Investigational Phase 3 65646-68-6
50
Levulinic acid Experimental Phase 3 123-76-2 11579
51
Cobalamin Experimental Phase 3,Phase 2,Not Applicable 13408-78-1 6857388
52
Tremelimumab Investigational Phase 3,Phase 1,Phase 2 745013-59-6
53
Maleic acid Experimental, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 110-17-8, 110-16-7 444972
54
Cediranib Investigational Phase 2, Phase 3,Phase 3 288383-20-0 9933475
55
Apaziquone Investigational Phase 3 114560-48-4 5813717
56 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
57 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
58 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
59 Dermatologic Agents Phase 3,Phase 2,Phase 1
60 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
61 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
62 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
63 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
64 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
65 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
66 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
67 Folate Phase 3,Phase 2,Phase 1,Not Applicable
68 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
69 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
70 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
71 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
72 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Early Phase 1
73 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
74 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
75 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
76 Liposomal amphotericin B Phase 2, Phase 3
77 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
78 Protective Agents Phase 3,Phase 2,Early Phase 1
79 Nutrients Phase 3,Phase 2,Early Phase 1,Not Applicable
80 Tocopherols Phase 3
81 Trace Elements Phase 3,Phase 2,Early Phase 1,Not Applicable
82 Micronutrients Phase 3,Phase 2,Early Phase 1,Not Applicable
83 Tocotrienols Phase 3
84 Antioxidants Phase 3,Phase 2
85 Vitamins Phase 3,Phase 2,Not Applicable
86 Pharmaceutical Solutions Phase 2, Phase 3,Phase 3,Phase 1
87 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
88 Vaccines Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
89 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
90 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
91 Mitomycins Phase 3,Phase 2,Not Applicable,Early Phase 1
92 Lipid Regulating Agents Phase 3,Phase 2
93 Hypolipidemic Agents Phase 3,Phase 2
94 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
95 Angiogenesis Modulating Agents Phase 3,Phase 1,Phase 2
96 Angiogenesis Inhibitors Phase 3,Phase 1,Phase 2
97 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
98 Mitogens Phase 3,Phase 2,Phase 1
99 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
100 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
101 taxane Phase 2, Phase 3,Phase 3,Phase 1
102 Photosensitizing Agents Phase 3
103 Antiparasitic Agents Phase 3,Phase 1
104 Antiprotozoal Agents Phase 3,Phase 1
105 Vitamin B3 Phase 3
106 Nicotinic Acids Phase 3
107 Vasodilator Agents Phase 3
108 Immunoglobulin G Phase 3,Phase 2,Phase 1
109 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
110 Vitamin B12 Phase 3,Phase 2,Not Applicable
111 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
112
protease inhibitors Phase 3,Phase 2,Phase 1
113 Hormones Phase 3,Phase 2,Phase 1
114 Gastrointestinal Agents Phase 3,Phase 2
115 Antiemetics Phase 3,Phase 2
116 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
117 glucocorticoids Phase 3,Phase 2,Phase 1
118 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
119 Hematinics Phase 3,Phase 2,Not Applicable
120 Autonomic Agents Phase 3,Phase 2,Early Phase 1
121 Anti-Inflammatory Agents Phase 3,Phase 2,Not Applicable
122 Vitamin B 12 Phase 3,Phase 2,Not Applicable
123 Hormone Antagonists Phase 3,Phase 2,Phase 1
124 BB 1101 Phase 3,Phase 2
125 topoisomerase I inhibitors Phase 2, Phase 3,Phase 1
126 interferons Phase 2, Phase 3,Phase 1,Not Applicable
127 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
128 Carotenoids Phase 3
129 Fluoroquinolones Phase 3
130 Cytochrome P-450 Enzyme Inhibitors Phase 3
131 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
132
Nintedanib Approved Phase 2 656247-17-5 56843413
133
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
134
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
135
Sunitinib Approved, Investigational Phase 1, Phase 2,Phase 2 557795-19-4, 341031-54-7 5329102
136
Metformin Approved Phase 2 657-24-9 14219 4091
137
Simvastatin Approved Phase 2 79902-63-9 54454